Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer.

Purpose: To determine the efficacy of gemcitabine (GEM) plus vinorelbine (VRL) administered biweekly in pretreated patients with advanced breast cancer.

Patients And Methods: Advanced breast cancer patients without response, with stable disease, or with recurrence within 6 months of prior treatment were given GEM 1,000 mg/m(2) and VRL 25 mg/m(2), once every 2 weeks for at least six cycles.

Results: Of the 51 patients enrolled, 50 (median, age 58 years; range, 34 to 76 years) were assessable.